Sandy Mong, MD

Sandy is the senior vice president of business development & operations at Curie Therapeutics Inc. Prior to joining Curie, she was an entrepreneur in-residence at Atlas Venture. Sandy was previously vice president of business development & operations at BridgeBio Pharma (NASDAQ: BBIO), where she focused on development operations for single asset subsidiaries, and supported modality agnostic asset acquisition and platform partnership. Prior to BridgeBio, Sandy was a senior director of business development & strategy at CRISPR Therapeutics (NASDAQ: CRSP), where she focused on hemoglobinopathies, regenerative medicine, and neuromuscular diseases, as well as search and evaluation for the gRNA / Cas9 and delivery platforms. Prior to CRISPR, Sandy was a consultant with McKinsey & Company. Sandy obtained her M.D. from Harvard Medical School, where she completed a Howard Hughes Medical Institute fellowship. She graduated with a B.S. in molecular, cellular, and developmental biology from Yale.